Desjardins Has Positive Outlook for TSE:INO FY2026 Earnings

Inovalis Real Estate Investment Trust (TSE:INO) – Equities researchers at Desjardins upped their FY2026 EPS estimates for Inovalis Real Estate Investment Trust in a research report issued on Wednesday, May 14th. Desjardins analyst A. Leon now anticipates that the company will post earnings per share of $0.01 for the year, up from their previous forecast of ($0.02).

Inovalis Real Estate Investment Trust Stock Performance

Inovalis Real Estate Investment Trust Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.